SCHEMBL1353055

SCHEMBL1353055

COc1ccc(C(N)=O)cc1C(=O)Nc1ccccc1SC

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.68
HSD17B10 Q99714 3/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
ALDH1A1 P00352 6/20 0.57
KMT2A Q03164 7/20 0.56
MEN1 O00255 6/20 0.56
RAB9A P51151 3/20 0.56
MAPT P10636 1/20 0.56
NPC1 O15118 1/20 0.54
POLB P06746 1/20 0.53
HPGD P15428 2/20 0.53
PKM P14618 1/20 0.52
CRHBP P24387 1/20 0.52
CRHR2 Q13324 1/20 0.52
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
CHEK1 O14757 1/20 0.51
PIM1 P11309 1/20 0.51
MAPK8 P45983 1/20 0.51
CLK4 Q9HAZ1 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1353113 0.87 RAB9A (0.64) TSHRHSD17B10SMN1; SMN2ALDH1A1KMT2A
SCHEMBL1353420 0.85 KDM4E (0.56) TSHRHSD17B10ALDH1A1KMT2AMEN1
SCHEMBL1352789 0.84 CHEK1 (0.58) TSHRHSD17B10ALDH1A1KMT2AMEN1
SCHEMBL1354395 0.84 PDE4D (0.70) ALDH1A1KMT2AMEN1RAB9AMAPT
SCHEMBL1351225 0.84 PDE4D (0.57) SMN1; SMN2ALDH1A1KMT2AMEN1RAB9A
SCHEMBL1351165 0.82 ALDH1A1 (0.64) HSD17B10SMN1; SMN2ALDH1A1KMT2AMEN1
SCHEMBL1351176 0.80 KCNK3 (0.55) TSHRHSD17B10SMN1; SMN2ALDH1A1KMT2A
SCHEMBL1353162 0.80 PDE4D (0.57) SMN1; SMN2ALDH1A1KMT2AMEN1RAB9A
SCHEMBL1353257 0.79 TP53 (0.68) TSHRHSD17B10SMN1; SMN2ALDH1A1KMT2A
SCHEMBL1353007 0.78 SMN1; SMN2 (0.66) TSHRSMN1; SMN2ALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063046-B2 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-11-22 US disclosed
US-8063046-B2 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-11-22 US disclosed
EP-1698618-B1 BENZAMIDE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2011-05-18 EP disclosed
US-20100179326-A1 BENZAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-07-15 US disclosed
US-20100179326-A1 BENZAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-07-15 US disclosed
US-20100179326-A1 BENZAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-07-15 US disclosed
US-7705053-B2 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-04-27 US disclosed
US-7705053-B2 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-04-27 US disclosed
US-7705053-B2 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-04-27 US disclosed
US-20070123493-A1 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-05-31 US disclosed
US-20070123493-A1 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-05-31 US disclosed
US-20070123493-A1 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-05-31 US disclosed
EP-1698618-A1 BENZAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123493-A1 Benzamide derivative BDKRB1, BDKRB2, NR1H2 TSHR 1244/4885HSD17B10 315/4885SMN1; SMN2 3867/4885
US-20100179326-A1 BENZAMIDE DERIVATIVE NR0B2, NR1H2, CNR2 TSHR 1419/4885HSD17B10 540/4885SMN1; SMN2 3723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.